GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU4563197A
(en)
*
|
1996-10-01 |
1998-04-24 |
Celltech Therapeutics Limited |
Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US6147080A
(en)
*
|
1996-12-18 |
2000-11-14 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
US5945418A
(en)
*
|
1996-12-18 |
1999-08-31 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
US6608060B1
(en)
|
1996-12-18 |
2003-08-19 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
AU5330698A
(en)
*
|
1996-12-23 |
1998-07-17 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
*
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE69839735D1
(de)
|
1997-12-15 |
2008-08-28 |
Astellas Pharma Inc |
Pyrimidin-5-carboxamid-derivate
|
KR100643419B1
(ko)
|
1998-03-27 |
2006-11-10 |
얀센 파마슈티카 엔.브이. |
Hiv를 억제하는 피리미딘 유도체
|
US6562833B1
(en)
|
1998-06-10 |
2003-05-13 |
Basf Aktiengesellschaft |
Use of 2-(n-phenylamino)pyrimidines as fungicides, and novel 2-(n-phenylamino) pyrimidines
|
US6846799B1
(en)
|
1998-08-18 |
2005-01-25 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
US7354894B2
(en)
|
1998-08-18 |
2008-04-08 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of EGF-R antagonists
|
CA2337422C
(en)
*
|
1998-08-18 |
2010-11-02 |
The Regents Of The University Of California |
Preventing airway mucus production by administration of egf-r antagonists
|
WO2000012485A1
(en)
*
|
1998-08-29 |
2000-03-09 |
Astrazeneca Ab |
Pyrimidine compounds
|
US6632820B1
(en)
|
1998-08-29 |
2003-10-14 |
Astrazeneca Ab |
Pyrimidine compounds
|
HU230394B1
(hu)
|
1998-11-10 |
2016-04-28 |
Janssen Pharmaceutica N.V. |
HIV-vírus szaporodását gátló pirimidin-származékok
|
GB9828511D0
(en)
|
1998-12-24 |
1999-02-17 |
Zeneca Ltd |
Chemical compounds
|
GB9905075D0
(en)
|
1999-03-06 |
1999-04-28 |
Zeneca Ltd |
Chemical compounds
|
GB9907658D0
(en)
|
1999-04-06 |
1999-05-26 |
Zeneca Ltd |
Chemical compounds
|
WO2000075113A1
(fr)
|
1999-06-09 |
2000-12-14 |
Yamanouchi Pharmaceutical Co., Ltd. |
Nouveaux derives carboxamide heterocycliques
|
EP1206260A4
(de)
|
1999-06-30 |
2002-10-30 |
Merck & Co Inc |
Src-kinase hemmende verbindungen
|
ATE253915T1
(de)
|
1999-06-30 |
2003-11-15 |
Merck & Co Inc |
Src-kinase hemmende verbindungen
|
WO2001000214A1
(en)
*
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
US6432979B1
(en)
|
1999-08-12 |
2002-08-13 |
American Cyanamid Company |
Method of treating or inhibiting colonic polyps and colorectal cancer
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
WO2001017995A1
(en)
|
1999-09-10 |
2001-03-15 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
BRPI0014271B1
(pt)
|
1999-09-24 |
2021-06-22 |
Janssen Pharmaceutica N.V. |
Partícula consistindo em uma dispersão de sólidos, uso da dita partícula, dispersão de sólidos, forma de dosagem farmacêutica, bem como processos de preparação de dita partícula, dispersão e forma de dosagem
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
WO2001025220A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Amgen Inc. |
Triazine kinase inhibitors
|
GB9924862D0
(en)
*
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
US7101869B2
(en)
|
1999-11-30 |
2006-09-05 |
Pfizer Inc. |
2,4-diaminopyrimidine compounds useful as immunosuppressants
|
EE200200275A
(et)
*
|
1999-11-30 |
2003-10-15 |
Pfizer Products Inc. |
Immunosupressantidena kasutatavad 2,4-diaminopürimidiiniühendid
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
MXPA02006324A
(es)
|
1999-12-23 |
2002-12-13 |
Pfizer Prod Inc |
Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
|
CA2394727A1
(en)
*
|
1999-12-28 |
2001-07-05 |
Pharmacopeia, Inc. |
Pyrimidine and triazine kinase inhibitors
|
WO2001060816A1
(en)
*
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
GB0004890D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004887D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB2361236B
(en)
|
2000-03-29 |
2002-04-24 |
Cyclacel Ltd |
Pyrimidines useful against proliferative disorders
|
CA2406562C
(en)
*
|
2000-05-08 |
2009-09-15 |
Janssen Pharmaceutica N.V. |
Hiv replication inhibiting pyrimidines and triazines
|
ES2559273T3
(es)
|
2000-05-08 |
2016-02-11 |
Janssen Pharmaceutica Nv |
Profármacos de pirimidinas que inhiben la replicación del VIH
|
GB0016877D0
(en)
|
2000-07-11 |
2000-08-30 |
Astrazeneca Ab |
Chemical compounds
|
JP2004505094A
(ja)
*
|
2000-07-31 |
2004-02-19 |
ユニバーシティ・オブ・メリーランド, ボルティモア |
免疫調節化合物
|
GB0021726D0
(en)
|
2000-09-05 |
2000-10-18 |
Astrazeneca Ab |
Chemical compounds
|
WO2002022605A1
(en)
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6989385B2
(en)
|
2000-12-21 |
2006-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US7105530B2
(en)
|
2000-12-21 |
2006-09-12 |
Smithkline Beecham Corporation |
Pyrimidineamines as angiogenesis modulators
|
GB0103926D0
(en)
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
ES2316546T3
(es)
*
|
2001-02-20 |
2009-04-16 |
Astrazeneca Ab |
2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
|
SE0100569D0
(sv)
*
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
EP1379520B2
(de)
*
|
2001-02-23 |
2014-04-09 |
Merck Sharp & Dohme Corp. |
N-substituierte nichtaryl-heterocyclische nmda/nr2b antagonisten
|
GB0107901D0
(en)
*
|
2001-03-29 |
2001-05-23 |
Cyclacel Ltd |
Anti-cancer compounds
|
ES2292753T4
(es)
*
|
2001-03-29 |
2009-02-16 |
Vertex Pharmaceuticals Incorporated |
Inhibidores de quinasas n-terminales c-jun (jnk) y otras proteina quinasas.
|
US6864255B2
(en)
|
2001-04-11 |
2005-03-08 |
Amgen Inc. |
Substituted triazinyl amide derivatives and methods of use
|
US6881737B2
(en)
*
|
2001-04-11 |
2005-04-19 |
Amgen Inc. |
Substituted triazinyl acrylamide derivatives and methods of use
|
CN100480242C
(zh)
*
|
2001-05-29 |
2009-04-22 |
舍林股份公司 |
Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
|
DE10127581A1
(de)
*
|
2001-05-29 |
2003-01-02 |
Schering Ag |
CDK inhibitorische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
GB0113041D0
(en)
|
2001-05-30 |
2001-07-18 |
Astrazeneca Ab |
Chemical compounds
|
US6762179B2
(en)
|
2001-05-31 |
2004-07-13 |
Vertex Pharmaceuticals Incorporated |
Thiazole compounds useful as inhibitors of protein kinase
|
ATE339418T1
(de)
*
|
2001-06-01 |
2006-10-15 |
Vertex Pharma |
Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
|
JP4541695B2
(ja)
*
|
2001-06-15 |
2010-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテインキナーゼインヒビターとしての5−(2−アミノピリミジン−4−イル)ベンズイソキサゾール
|
US20040171630A1
(en)
*
|
2001-06-19 |
2004-09-02 |
Yuntae Kim |
Tyrosine kinase inhibitors
|
JP2004535437A
(ja)
|
2001-06-22 |
2004-11-25 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害剤
|
US7678805B2
(en)
*
|
2001-06-29 |
2010-03-16 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (IBD)
|
JP2005500041A
(ja)
*
|
2001-06-29 |
2005-01-06 |
アブ サイエンス |
強力で選択的かつ非毒性のc−kit阻害剤
|
ATE330608T1
(de)
*
|
2001-06-29 |
2006-07-15 |
Ab Science |
Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
|
US7700610B2
(en)
*
|
2001-06-29 |
2010-04-20 |
Ab Science |
Use of tyrosine kinase inhibitors for treating allergic diseases
|
US20050176687A1
(en)
*
|
2001-06-29 |
2005-08-11 |
Alain Moussy |
Use of tyrosine kinase inhibitors for treating autoimmune diseases
|
EP1401412A2
(de)
*
|
2001-06-29 |
2004-03-31 |
AB Science |
Verwendung von potenten, selektiven und nontoxischen c-kithemmer zur behandlung von tumorangiogenese
|
US8101629B2
(en)
*
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
JO3429B1
(ar)
*
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US7638522B2
(en)
*
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US6939874B2
(en)
*
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
*
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
WO2003020702A2
(en)
|
2001-08-31 |
2003-03-13 |
The Rockefeller University |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
US20040242612A1
(en)
*
|
2001-09-20 |
2004-12-02 |
Alain Moussy |
Use of tyrosine kinase inhibitors for promoting hair growth
|
DE60228278D1
(de)
*
|
2001-09-20 |
2008-09-25 |
Ab Science |
Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
|
WO2003030909A1
(en)
*
|
2001-09-25 |
2003-04-17 |
Bayer Pharmaceuticals Corporation |
2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
|
WO2003026666A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Pharmaceuticals Corporation |
2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
|
JP4495963B2
(ja)
|
2001-09-28 |
2010-07-07 |
サイクラセル リミテッド |
抗増殖性化合物としてのn−(4−(4−メチルチアゾール−5−イル)ピリミジン−2−イル)−n−フェニルアミン類
|
CA2463989C
(en)
|
2001-10-17 |
2012-01-31 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
|
WO2003032994A2
(de)
|
2001-10-17 |
2003-04-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
|
AU2002363174B2
(en)
*
|
2001-11-01 |
2008-09-25 |
Janssen Pharmaceutica N.V. |
Amide derivatives as glycogen synthase kinase 3-beta inhibitors
|
MXPA04004178A
(es)
*
|
2001-11-01 |
2004-09-06 |
Janssen Pharmaceutica Nv |
Heteroarilaminas como inhibidores de glucogeno cintasa cinasa 3beta.
|
PL370531A1
(en)
*
|
2001-11-28 |
2005-05-30 |
Btg International Ltd |
Preventives or remedies for alzheimer's disease or amyloid protein fibrosis inhibitors containing nitrogen-containing heteroaryl compounds
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
AU2002367172A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
WO2003062225A1
(en)
*
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
AR038368A1
(es)
|
2002-02-01 |
2005-01-12 |
Novartis Ag |
Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
|
TWI329105B
(en)
*
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
WO2003066601A1
(en)
|
2002-02-08 |
2003-08-14 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
WO2003072090A2
(en)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
EP1487824B1
(de)
|
2002-03-01 |
2007-06-20 |
SmithKline Beecham Corporation |
Diaminopyrimidine und deren verwendung als angiogenesehemmer
|
GB0205690D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0205693D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
WO2003076434A1
(en)
|
2002-03-09 |
2003-09-18 |
Astrazeneca Ab |
4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
|
GB0205688D0
(en)
|
2002-03-09 |
2002-04-24 |
Astrazeneca Ab |
Chemical compounds
|
GB0206215D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
AU2003231231A1
(en)
*
|
2002-05-06 |
2003-11-11 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
WO2004000318A2
(en)
*
|
2002-06-21 |
2003-12-31 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
ES2400339T3
(es)
*
|
2002-07-15 |
2013-04-09 |
Symphony Evolution, Inc. |
Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
DE10233737A1
(de)
*
|
2002-07-24 |
2004-02-05 |
Morphochem Aktiengesellschaft für kombinatorische Chemie |
Verwendung von Modulatoren des Signaltransduktionswegs über die Proteinkinase Fyn zur Behandlung von Tumorerkrankungen
|
EP1534286B1
(de)
*
|
2002-07-29 |
2009-12-09 |
Rigel Pharmaceuticals, Inc. |
VERFAHREN ZUR BEHANDLUNG ODER PRûVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
|
KR101297924B1
(ko)
*
|
2002-07-29 |
2013-08-20 |
리겔 파마슈티칼스, 인크. |
2,4-피리미딘디아민 화합물을 이용한 자가면역질환의 치료및 예방 방법
|
SI1534286T1
(sl)
|
2002-07-29 |
2010-04-30 |
Rigel Pharmaceuticals Inc |
Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
|
DE60313339T2
(de)
*
|
2002-07-31 |
2008-01-03 |
Critical Outcome Technologies, Inc. |
Protein tyrosin kinase inhibitoren
|
EA200500299A1
(ru)
|
2002-08-02 |
2005-08-25 |
Вертекс Фармасьютикалз Инкорпорейтед |
Пиразольные композиции, используемые в качестве ингибиторов gsk-3
|
CN102702111B
(zh)
*
|
2002-08-09 |
2014-12-17 |
詹森药业有限公司 |
制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法
|
CA2495386C
(en)
|
2002-08-14 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Protein kinase inhibitors and uses thereof
|
DE10239042A1
(de)
*
|
2002-08-21 |
2004-03-04 |
Schering Ag |
Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
|
AU2003273675A1
(en)
*
|
2002-10-09 |
2004-05-04 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
JP2006512314A
(ja)
*
|
2002-11-01 |
2006-04-13 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Jakインヒビターおよび他のプロテインキナーゼインヒビターとしての組成物の使用
|
AU2003295396B2
(en)
*
|
2002-11-04 |
2009-02-26 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl-pyramidine derivatives as JAK inhibitors
|
EP1560824A1
(de)
|
2002-11-05 |
2005-08-10 |
Vertex Pharmaceuticals Incorporated |
Verbindungen, die als inhibitoren von jak und anderen proteasen anwendbar sind
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
AU2003297160A1
(en)
|
2002-12-18 |
2004-07-22 |
Vertex Pharmaceuticals Incorporated |
Benzisoxazole derivatives useful as inhibitors of protein kinases
|
GB0229581D0
(en)
*
|
2002-12-19 |
2003-01-22 |
Cyclacel Ltd |
Use
|
US7109337B2
(en)
|
2002-12-20 |
2006-09-19 |
Pfizer Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
ATE458731T1
(de)
*
|
2002-12-20 |
2010-03-15 |
Pfizer Prod Inc |
Pyrimidin-derivate zur behandlung von anormalem zellwachstum
|
UA80767C2
(en)
*
|
2002-12-20 |
2007-10-25 |
Pfizer Prod Inc |
Pyrimidine derivatives for the treatment of abnormal cell growth
|
ATE440087T1
(de)
|
2003-01-30 |
2009-09-15 |
Boehringer Ingelheim Pharma |
2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
|
BRPI0407329A
(pt)
|
2003-02-07 |
2006-01-10 |
Janssen Pharmaceutica Nv |
Derivados de pirimidina para a prevenção de infecção de hiv
|
WO2004074244A2
(en)
*
|
2003-02-20 |
2004-09-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
GB0305929D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
DE602004014117D1
(de)
*
|
2003-03-25 |
2008-07-10 |
Vertex Pharma |
Thiazole zur verwendung als inhibitoren von protein-kinasen
|
GB0311274D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
GB0311276D0
(en)
|
2003-05-16 |
2003-06-18 |
Astrazeneca Ab |
Chemical compounds
|
DK1656372T3
(da)
*
|
2003-07-30 |
2013-07-01 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
|
CA2533474A1
(en)
|
2003-07-30 |
2005-02-10 |
Shudong Wang |
2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
|
ES2365223T3
(es)
*
|
2003-08-07 |
2011-09-26 |
Rigel Pharmaceuticals, Inc. |
Compuestos 2,4-pirimidindiamínicos y usos como agentes antiproliferativos.
|
EP1660458B1
(de)
*
|
2003-08-15 |
2012-01-25 |
Novartis AG |
Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine
|
GB0321710D0
(en)
*
|
2003-09-16 |
2003-10-15 |
Novartis Ag |
Organic compounds
|
JP2007505858A
(ja)
*
|
2003-09-18 |
2007-03-15 |
ノバルティス アクチエンゲゼルシャフト |
増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン
|
JP4638436B2
(ja)
|
2003-09-26 |
2011-02-23 |
エグゼリクシス, インコーポレイテッド |
c−Metモジュレーターおよびその使用
|
JP2007507529A
(ja)
*
|
2003-09-30 |
2007-03-29 |
サイオス・インコーポレーテツド |
複素環式アミドおよびスルホンアミド
|
EP1678169B1
(de)
|
2003-10-17 |
2009-07-22 |
Astrazeneca AB |
4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
|
AU2004285745A1
(en)
|
2003-10-21 |
2005-05-12 |
Cyclacel Limited |
Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy
|
GB0324599D0
(en)
*
|
2003-10-21 |
2003-11-26 |
Cyclacel Ltd |
Compound
|
SG139747A1
(en)
|
2003-11-18 |
2008-02-29 |
Novartis Ag |
Inhibitors of the mutant form of kit
|
JP4772690B2
(ja)
|
2003-12-03 |
2011-09-14 |
ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド |
チューブリン阻害剤
|
TW200528101A
(en)
|
2004-02-03 |
2005-09-01 |
Astrazeneca Ab |
Chemical compounds
|
GB0402653D0
(en)
*
|
2004-02-06 |
2004-03-10 |
Cyclacel Ltd |
Compounds
|
BRPI0510980A
(pt)
|
2004-05-14 |
2007-11-27 |
Pfizer Prod Inc |
derivados de pirimidina para o tratamento do crescimento anormal de células
|
BRPI0510963A
(pt)
|
2004-05-14 |
2007-11-20 |
Pfizer Prod Inc |
derivados pirimidina para o tratamento do crescimento anormal de células
|
MXPA06011658A
(es)
|
2004-05-14 |
2006-12-14 |
Pfizer Prod Inc |
Derivados de pirimidina para el tratamiento del crecimiento celular anormal.
|
EP1763514A2
(de)
|
2004-05-18 |
2007-03-21 |
Rigel Pharmaceuticals, Inc. |
Cycloalkyl-substituierte pyrimidindiaminverbindungen und deren verwendung
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
GB0411791D0
(en)
*
|
2004-05-26 |
2004-06-30 |
Cyclacel Ltd |
Compounds
|
CA2571937A1
(en)
|
2004-07-08 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pyrimidine derivatives useful as inhibitors of pkc-theta
|
MX2007002169A
(es)
|
2004-08-27 |
2007-08-14 |
Cyclacel Ltd |
Inhibidores de cdk de purina y pirimidina y su uso para el tratamiento de enfermedades inmunes.
|
CN101437514B
(zh)
*
|
2004-10-22 |
2012-04-25 |
詹森药业有限公司 |
C-fms激酶抑制剂
|
US7645755B2
(en)
*
|
2004-10-22 |
2010-01-12 |
Janssen Pharmaceutical N.V. |
Inhibitors of c-fms kinase
|
NZ555289A
(en)
*
|
2004-10-22 |
2010-10-29 |
Janssen Pharmaceutica Nv |
Inhibitors of c-fms kinase
|
WO2006068770A1
(en)
*
|
2004-11-24 |
2006-06-29 |
Rigel Pharmaceuticals, Inc. |
Spiro-2, 4-pyrimidinediamine compounds and their uses
|
JP4932735B2
(ja)
|
2004-12-17 |
2012-05-16 |
アムジエン・インコーポレーテツド |
アミノピリミジン化合物および使用方法
|
GB0500492D0
(en)
*
|
2005-01-11 |
2005-02-16 |
Cyclacel Ltd |
Compound
|
CA2591948C
(en)
|
2005-01-19 |
2013-11-12 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
PL1853588T3
(pl)
|
2005-02-16 |
2008-11-28 |
Astrazeneca Ab |
Związki chemiczne
|
US8227455B2
(en)
*
|
2005-04-18 |
2012-07-24 |
Rigel Pharmaceuticals, Inc. |
Methods of treating cell proliferative disorders
|
US20080176879A1
(en)
|
2005-05-02 |
2008-07-24 |
Leila Alland |
Pyrimidylaminobenzamide Derivatives For Sytemic Mastocytosis
|
EP1883302A4
(de)
*
|
2005-05-03 |
2009-05-20 |
Rigel Pharmaceuticals Inc |
Jak-kinase-hemmer und deren verwendung
|
MX2007014328A
(es)
|
2005-05-16 |
2008-02-12 |
Astrazeneca Ab |
Compuestos quimicos.
|
AU2006255028B2
(en)
|
2005-06-06 |
2012-04-19 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
US20070203161A1
(en)
*
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
JP5225079B2
(ja)
|
2005-06-08 |
2013-07-03 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Jak経路の阻害のための組成物および方法
|
US20060281788A1
(en)
*
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
WO2007025103A2
(en)
*
|
2005-08-23 |
2007-03-01 |
Intra-Cellular Therapies, Inc. |
Organic compounds for treating reduced dopamine receptor signalling activity
|
EP2275095A3
(de)
*
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenese durch modulation des Muscarinrezeptors
|
EP1934213A1
(de)
|
2005-09-30 |
2008-06-25 |
Astra Zeneca AB |
Imidazo [1,2-a] pyridin mit antizellproliferationswirkung
|
GB0520955D0
(en)
*
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
GB0520958D0
(en)
*
|
2005-10-14 |
2005-11-23 |
Cyclacel Ltd |
Compound
|
AU2006307657B2
(en)
|
2005-10-28 |
2010-10-28 |
Astrazeneca Ab |
4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
EP1951684B1
(de)
*
|
2005-11-01 |
2016-07-13 |
TargeGen, Inc. |
Biarylmetapyrimidinkinaseinhibitoren
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
NZ594383A
(en)
|
2005-11-03 |
2013-05-31 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
AU2006311910A1
(en)
*
|
2005-11-03 |
2007-05-18 |
Irm Llc |
Protein kinase inhibitors
|
EP1948647A1
(de)
|
2005-11-03 |
2008-07-30 |
SGX Pharmaceuticals, Inc. |
Pyrimidinylthiophenverbindungen als kinasemodulatoren
|
US7713987B2
(en)
*
|
2005-12-06 |
2010-05-11 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2,4-diamines and their uses
|
WO2007073117A1
(en)
*
|
2005-12-22 |
2007-06-28 |
Crystalgenomics, Inc. |
Aminopyrimidine derivatives inhibiting protein kinase activity, method for the preparation thereof and pharmaceutical composition containing same
|
WO2007089768A2
(en)
*
|
2006-01-30 |
2007-08-09 |
Exelixis, Inc. |
4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them
|
CA2642211C
(en)
*
|
2006-02-17 |
2012-01-24 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
|
EP1991532B1
(de)
|
2006-02-24 |
2017-01-11 |
Rigel Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung des jak-pfades
|
MX2008013533A
(es)
|
2006-04-20 |
2009-01-15 |
Janssen Pharmaceutica Nv |
Compuestos heterociclicos como inhibidores de c-fms cinasa.
|
CA2649924C
(en)
|
2006-04-20 |
2014-08-19 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
EP2021329B1
(de)
*
|
2006-04-20 |
2016-04-13 |
Janssen Pharmaceutica N.V. |
Inhibitoren von c-fms-kinase
|
CA2655315A1
(en)
|
2006-06-15 |
2007-12-21 |
Boehringer Ingelheim International Gmbh |
2-anilino-4-aminoalkyleneaminopyrimidines
|
KR20090019011A
(ko)
*
|
2006-06-15 |
2009-02-24 |
베링거 인겔하임 인터내셔날 게엠베하 |
단백질 키나아제 c-알파의 억제제로서의 2-아닐리노-4-(헤테로사이클릭)아미노-피리미딘
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
ES2380551T3
(es)
|
2006-11-21 |
2012-05-16 |
Rigel Pharmaceuticals, Inc. |
Sales de profármaco de compuestos de 2,4-pirimidindiamina y sus usos
|
JP5837278B2
(ja)
|
2006-12-05 |
2015-12-24 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
新規使用
|
ES2524009T3
(es)
*
|
2006-12-08 |
2014-12-03 |
Irm Llc |
Compuestos y composiciones como inhibidores de la proteína quinasa
|
BRPI0720635A2
(pt)
*
|
2006-12-22 |
2014-01-07 |
Novartis Ag |
Compostos orgânicos e seus usos
|
JP5571387B2
(ja)
|
2007-01-11 |
2014-08-13 |
クリティカル・アウトカム・テクノロジーズ・インコーポレイテッド |
癌の治療のための化合物および方法
|
US8138191B2
(en)
|
2007-01-11 |
2012-03-20 |
Critical Outcome Technologies Inc. |
Inhibitor compounds and cancer treatment methods
|
US8846704B2
(en)
*
|
2007-01-31 |
2014-09-30 |
YM Biosciences Austraila Pty Ltd |
Thiopyrimidine-based compounds and uses thereof
|
KR101737753B1
(ko)
*
|
2007-03-12 |
2017-05-18 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
JP5389785B2
(ja)
|
2007-05-02 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤として有用なチアゾールおよびピラゾール
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
KR20100049068A
(ko)
*
|
2007-07-17 |
2010-05-11 |
리겔 파마슈티칼스, 인크. |
Pkc 억제제로서의 시클릭 아민 치환된 피리미딘디아민
|
NZ582879A
(en)
|
2007-07-31 |
2012-03-30 |
Vertex Pharma |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
WO2009017838A2
(en)
*
|
2007-08-01 |
2009-02-05 |
Exelixis, Inc. |
Combinations of jak-2 inhibitors and other agents
|
PT2200436E
(pt)
*
|
2007-09-04 |
2015-04-29 |
Scripps Research Inst |
Pirimidinilaminas substituídas como inibidoras da proteína quinase
|
JO3240B1
(ar)
*
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
JP2011032169A
(ja)
*
|
2007-12-11 |
2011-02-17 |
Genecare Research Institute Co Ltd |
4−アミノピリミジン誘導体および該化合物を含有する医薬組成物
|
US8466151B2
(en)
*
|
2007-12-26 |
2013-06-18 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
MX2010012703A
(es)
|
2008-05-21 |
2010-12-21 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
WO2009158571A1
(en)
*
|
2008-06-27 |
2009-12-30 |
Avila Therapeutics And Uses Thereof |
Heteroaryl compounds and uses thereof
|
US8338439B2
(en)
*
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
KR20110050549A
(ko)
|
2008-09-03 |
2011-05-13 |
버텍스 파마슈티칼스 인코포레이티드 |
공-결정 및 이를 포함하는 제약 제제
|
EP2349235A1
(de)
|
2008-11-07 |
2011-08-03 |
Triact Therapeutics, Inc. |
Verwendung von catecholbutan-derivaten in der krebstherapie
|
RU2535032C2
(ru)
|
2008-12-22 |
2014-12-10 |
Милленниум Фармасьютикалз, Инк. |
Сочетание ингибиторов аврора киназы и анти-cd 20 антител
|
WO2010078369A2
(en)
|
2008-12-30 |
2010-07-08 |
Rigel Pharmaceuticals, Inc. |
Pyrimidinediamine kinase inhibitors
|
CA2749195C
(en)
*
|
2009-01-15 |
2017-03-07 |
Rigel Pharmaceuticals, Inc. |
Protein kinase c inhibitors and uses thereof
|
TWI577664B
(zh)
|
2009-01-16 |
2017-04-11 |
艾克塞里克斯公司 |
N-(4-{〔6,7-雙(甲氧基)喹啉-4-基〕氧基}苯基)-n’-(4-氟苯基)環丙烷-1,1-二甲醯胺蘋果酸鹽、包含其之醫藥組合物及其用途
|
WO2010090875A1
(en)
|
2009-01-21 |
2010-08-12 |
Rigel Pharmaceuticals, Inc. |
Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
|
NZ594323A
(en)
|
2009-01-23 |
2013-05-31 |
Rigel Pharmaceuticals Inc |
Compositions and methods for inhibition of the jak pathway
|
WO2010099139A2
(en)
|
2009-02-25 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Combination anti-cancer therapy
|
EP2400970A4
(de)
|
2009-02-25 |
2012-07-18 |
Intra Cellular Therapies Inc |
Pde-1-hemmer für augenleiden
|
US20110171124A1
(en)
|
2009-02-26 |
2011-07-14 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the EMT status of tumor cells in vivo
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
EP2408479A1
(de)
|
2009-03-18 |
2012-01-25 |
OSI Pharmaceuticals, LLC |
Kombinationskrebstherapie mit verabreichung eines egfr-hemmers und eines igf-1r-hemmers
|
EP2440559B1
(de)
|
2009-05-05 |
2018-01-10 |
Dana-Farber Cancer Institute, Inc. |
Egfr-hemmer und verfahren zur krankheitsbehandlung damit
|
WO2010132127A1
(en)
|
2009-05-13 |
2010-11-18 |
Intra-Cellular Therapies, Inc. |
Organic compounds
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
EP2459195A1
(de)
*
|
2009-07-28 |
2012-06-06 |
Rigel Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung des jak-signalweges
|
WO2011016861A2
(en)
|
2009-08-05 |
2011-02-10 |
Intra-Cellular Therapies, Inc. |
Novel regulatory proteins and inhibitors
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
CA2780875A1
(en)
|
2009-11-13 |
2011-05-19 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
WO2011068898A1
(en)
|
2009-12-01 |
2011-06-09 |
Rigel Pharmaceuticals, Inc. |
Protein kinase c inhibitors and uses thereof
|
CA2788450A1
(en)
|
2009-12-30 |
2011-07-07 |
Arqule, Inc. |
Substituted naphthalenyl-pyrimidine compounds
|
EP2536279A4
(de)
|
2010-02-19 |
2013-07-24 |
Millennium Pharm Inc |
Kristalline formen von natrium-4-{[9-chlor-7-(2-fluor-6-methoxyphenyl)-5h -pyrimido-[5,4-d-][2-]benzazepin-2yl-]amino-}-2-methoxybenzoat
|
CA2999435A1
(en)
|
2010-04-01 |
2011-10-06 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of hiv
|
JP6035238B2
(ja)
|
2010-07-21 |
2016-11-30 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
プロテインキナーゼc阻害剤およびその使用
|
KR101937495B1
(ko)
|
2010-07-28 |
2019-01-10 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
WO2012021444A1
(en)
|
2010-08-10 |
2012-02-16 |
Avila Therapeutics, Inc. |
Besylate salt of a btk inhibitor
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
TWI545115B
(zh)
|
2010-11-01 |
2016-08-11 |
阿維拉製藥公司 |
雜環化合物及其用途
|
CA2816957A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
変異体選択的egfr阻害剤およびその使用
|
EP2468883A1
(de)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
EP2492688A1
(de)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
HUE046988T2
(hu)
|
2011-04-01 |
2020-04-28 |
Univ Utah Res Found |
Szubsztituált N-fenilpirimidin-2-amin analógok mint AXL kináz inhibitorok
|
US8703767B2
(en)
|
2011-04-01 |
2014-04-22 |
University Of Utah Research Foundation |
Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
AU2012250517B2
(en)
|
2011-05-04 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
EA029488B1
(ru)
|
2011-07-27 |
2018-04-30 |
Астразенека Аб |
Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
|
US20130084286A1
(en)
|
2011-08-31 |
2013-04-04 |
Thomas E. Januario |
Diagnostic markers
|
CN104066851A
(zh)
|
2011-09-30 |
2014-09-24 |
基因泰克公司 |
肿瘤或肿瘤细胞中上皮或间充质表型的诊断性甲基化标志物和对egfr激酶抑制剂的响应
|
AR088570A1
(es)
|
2011-10-28 |
2014-06-18 |
Celgene Avilomics Res Inc |
Metodos para tratar una enfermedad o trastorno relacionado con la tirosina quinasa de bruton
|
WO2013138495A1
(en)
|
2012-03-15 |
2013-09-19 |
Celgene Avilomics Research, Inc. |
Solid forms of an epidermal growth factor receptor kinase inhibitor
|
EP2825042B1
(de)
|
2012-03-15 |
2018-08-01 |
Celgene CAR LLC |
Salze eines epidermalen wachstumsfaktor-rezeptor-kinase-hemmers
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
ES2658395T3
(es)
|
2012-04-04 |
2018-03-09 |
Rigel Pharmaceuticals, Inc. |
Inhibidores de proteína cinasa C y usos de los mismos
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
US8809359B2
(en)
|
2012-06-29 |
2014-08-19 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine bicyclic compounds and uses thereof
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
AU2013299922B2
(en)
|
2012-08-07 |
2018-06-21 |
Janssen Pharmaceutica Nv |
Process for the preparation of heterocyclic ester derivatives
|
KR20150067298A
(ko)
|
2012-10-04 |
2015-06-17 |
유니버시티 오브 유타 리서치 파운데이션 |
티로신 수용체 키나아제 btk 억제제로서의 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
|
KR102194611B1
(ko)
|
2012-10-04 |
2020-12-23 |
유니버시티 오브 유타 리서치 파운데이션 |
티로신 수용체 키나아제 btk 억제제로서 치환된 n-(3-(피리미딘-4-일)페닐)아크릴아미드 유사체
|
US9062068B2
(en)
|
2012-12-04 |
2015-06-23 |
Rigel Pharmaceuticals, Inc. |
Protein kinase C inhibitors and uses thereof
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
JP2016509012A
(ja)
|
2013-02-08 |
2016-03-24 |
セルジーン アビロミクス リサーチ, インコーポレイテッド |
Erk阻害剤およびそれらの使用
|
WO2014127331A1
(en)
|
2013-02-17 |
2014-08-21 |
Intra-Cellular Therapies, Inc. |
Novel uses
|
GB201303109D0
(en)
*
|
2013-02-21 |
2013-04-10 |
Domainex Ltd |
Novel pyrimidine compounds
|
EP2961412A4
(de)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
Krebstherapie
|
JP6421170B2
(ja)
|
2013-03-14 |
2018-11-07 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
プロテインキナーゼc阻害剤およびその使用
|
CA2905993C
(en)
*
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
ES2717688T3
(es)
|
2013-03-15 |
2019-06-24 |
Intra Cellular Therapies Inc |
Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
|
JP6437519B2
(ja)
|
2013-03-15 |
2018-12-12 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
US10150742B2
(en)
|
2013-03-15 |
2018-12-11 |
President And Fellows Of Harvard College |
Substituted heterocyclic compounds for treating or preventing viral infections
|
WO2014147246A1
(en)
|
2013-03-21 |
2014-09-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
|
EP2976086B1
(de)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Kombination aus katalytischen mtorc 1/2-inhibitoren und selektiven inhibitoren der aurora-a-kinase
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
TW201534597A
(zh)
*
|
2013-06-20 |
2015-09-16 |
Ab Science |
作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
|
CN103408501B
(zh)
*
|
2013-08-14 |
2016-03-09 |
合肥医工医药有限公司 |
苄基嘧啶衍生物、其制备方法及其医药用途
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
WO2015035410A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutic, Inc. |
Cancer therapy
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
PT3126352T
(pt)
|
2014-04-04 |
2018-12-27 |
Syros Pharmaceuticals Inc |
Inibidores da quinase dependente de ciclina 7 (cdk7)
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
TW202134236A
(zh)
|
2014-06-12 |
2021-09-16 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
JP6810613B2
(ja)
|
2014-06-20 |
2021-01-06 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
US10285992B2
(en)
|
2014-08-07 |
2019-05-14 |
Intra-Cellular Therapies, Inc. |
Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
|
JP6591530B2
(ja)
|
2014-08-07 |
2019-10-16 |
イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. |
有機化合物
|
WO2016025561A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Forms and compositions of an erk inhibitor
|
CN107106563B
(zh)
|
2014-09-17 |
2021-05-25 |
细胞内治疗公司 |
化合物和方法
|
AU2015371312B2
(en)
|
2014-12-24 |
2022-01-27 |
Genentech, Inc. |
Therapeutic, diagnostic and prognostic methods for cancer of the bladder
|
CN106188029B
(zh)
*
|
2015-05-05 |
2018-09-18 |
山东轩竹医药科技有限公司 |
二并环类间变性淋巴瘤激酶抑制剂
|
US10682354B2
(en)
|
2016-03-28 |
2020-06-16 |
Intra-Cellular Therapies, Inc. |
Compositions and methods
|
SI3442947T1
(sl)
*
|
2016-04-15 |
2023-10-30 |
Epizyme, Inc. |
Z aminom substituirane arilne ali heteroarilne spojine kot inhibitorji ehmt1 in ehmt2
|
US20180072718A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
JP7134168B6
(ja)
|
2016-09-12 |
2024-02-02 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
EP4001269A1
(de)
|
2016-12-22 |
2022-05-25 |
Amgen Inc. |
Benzoisothiazol-, isothiazolo[3,4-b]pyridin-, quinazolin-, phthalazin-, pyrido[2,3-d]pyridazin- und pyrido[2,3-d]pyrimidin-derivate als kras g12c inhibitoren zur behandlung von lungen-, bauchspeicheldrüsen- oder darmkrebs
|
EP3612181A4
(de)
|
2017-04-21 |
2021-01-06 |
Epizyme, Inc. |
Kombinationstherapien mit ehmt2-inhibitoren
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
JP7401442B2
(ja)
|
2018-01-31 |
2023-12-19 |
イントラ-セルラー・セラピーズ・インコーポレイテッド |
新規使用
|
BR112020020246A8
(pt)
|
2018-04-05 |
2022-10-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de cinase axl e uso dos mesmos
|
JP2021521170A
(ja)
|
2018-04-13 |
2021-08-26 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤
|
WO2019213526A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3788038B1
(de)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
EP3790886B1
(de)
|
2018-05-10 |
2024-06-26 |
Amgen Inc. |
Kras g12c-inhibitoren zur behandlung von krebs
|
WO2019232419A1
(en)
|
2018-06-01 |
2019-12-05 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
US20190375749A1
(en)
|
2018-06-11 |
2019-12-12 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
EP3807276A2
(de)
|
2018-06-12 |
2021-04-21 |
Amgen Inc. |
Einen piperazinring umfassende kras g12c-inhibitoren und ihre verwendung zur krebsbehandlung
|
MX2021000977A
(es)
|
2018-07-26 |
2021-04-12 |
Sumitomo Pharma Oncology Inc |
Metodos para tratar enfermedades asociadas con expresion anormal de receptor de activina a tipo 1 (acvr1) e inhibidores de acvr1 para uso en los mismos.
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
US20210393632A1
(en)
|
2018-10-04 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
EP3883565A1
(de)
|
2018-11-19 |
2021-09-29 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
AU2019401495A1
(en)
|
2018-12-20 |
2021-06-24 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
US20220073504A1
(en)
|
2018-12-20 |
2022-03-10 |
Amgen Inc. |
Kif18a inhibitors
|
US20220056015A1
(en)
|
2018-12-20 |
2022-02-24 |
Amgen Inc. |
Kif18a inhibitors
|
PE20211475A1
(es)
|
2018-12-20 |
2021-08-05 |
Amgen Inc |
Inhibidores de kif18a
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
SG11202109422WA
(en)
|
2019-03-01 |
2021-09-29 |
Revolution Medicines Inc |
Bicyclic heterocyclyl compounds and uses thereof
|
MX2021010319A
(es)
|
2019-03-01 |
2021-12-10 |
Revolution Medicines Inc |
Compuestos biciclicos de heteroarilo y usos de estos.
|
BR112021022105A2
(pt)
*
|
2019-05-05 |
2021-12-28 |
Qilu Regor Therapeutics Inc |
Inibidores de cdk
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
AR119009A1
(es)
*
|
2019-05-29 |
2021-11-17 |
Syngenta Crop Protection Ag |
Derivados de alcoxipiridina y alcoxipirimidina microbicidas
|
WO2021026101A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020324406A1
(en)
|
2019-08-02 |
2022-03-17 |
Amgen Inc. |
KIF18A inhibitors
|
MX2022001295A
(es)
|
2019-08-02 |
2022-02-22 |
Amgen Inc |
Inhibidores de kif18a.
|
JP2022542392A
(ja)
|
2019-08-02 |
2022-10-03 |
アムジエン・インコーポレーテツド |
Kif18a阻害剤としてのピリジン誘導体
|
CA3147443A1
(en)
|
2019-08-08 |
2021-02-11 |
Rigel Pharmaceuticals, Inc. |
Compounds and method for treating cytokine release syndrome
|
EP4048671A1
(de)
|
2019-10-24 |
2022-08-31 |
Amgen Inc. |
Pyridopyrimidinderivate als kras-sg12c- und kras-g12d-inhibitoren zur behandlung von krebs
|
MX2022005357A
(es)
|
2019-11-04 |
2022-06-02 |
Revolution Medicines Inc |
Inhibidores de ras.
|
AU2020379734A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4055028A1
(de)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras-inhibitoren
|
MX2022005525A
(es)
|
2019-11-08 |
2022-06-08 |
Revolution Medicines Inc |
Compuestos de heteroarilo bicíclicos y usos de estos.
|
US20230192681A1
(en)
|
2019-11-14 |
2023-06-22 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
WO2021097207A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
CN114980976A
(zh)
|
2019-11-27 |
2022-08-30 |
锐新医药公司 |
共价ras抑制剂及其用途
|
TW202140011A
(zh)
|
2020-01-07 |
2021-11-01 |
美商銳新醫藥公司 |
Shp2抑制劑給藥和治療癌症的方法
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
MX2023002248A
(es)
|
2020-09-03 |
2023-05-16 |
Revolution Medicines Inc |
Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
|
JP2023541916A
(ja)
|
2020-09-15 |
2023-10-04 |
レボリューション メディシンズ インコーポレイテッド |
がんの治療における、ras阻害剤としてのインドール誘導体
|
EP4267250A1
(de)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1-inhibitoren und verwendungen davon
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
KR20240017811A
(ko)
|
2021-05-05 |
2024-02-08 |
레볼루션 메디슨즈, 인크. |
암의 치료를 위한 ras 억제제
|
CA3217393A1
(en)
|
2021-05-05 |
2022-11-10 |
Elena S. Koltun |
Ras inhibitors
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
WO2023114954A1
(en)
|
2021-12-17 |
2023-06-22 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023150197A1
(en)
*
|
2022-02-03 |
2023-08-10 |
Nexys Therapeutics, Inc. |
Aryl hydrocarbon receptor agonists and uses thereof
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|
WO2024097653A1
(en)
|
2022-10-31 |
2024-05-10 |
Sumitomo Pharma America, Inc. |
Pim1 inhibitor for treating myeloproliferative neoplasms
|